CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective

Original Research2019 May 21 [Epub ahead of print]

JOURNAL:Catheter Cardiovasc Interv. Article Link

A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study

Chen Y, Yin T, Xi S et al. Keywords: DAPT; postdischarge bleeding; ACS; 1-year follow-up; ticagrelor; clopidogrel

FULL TEXT PDF